Market closedNon-fractional
Anavex/AVXL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Anavex
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Ticker
AVXL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
New York, United States
Employees
40
Website
www.anavex.com
Anavex Metrics
BasicAdvanced
$349M
Market cap
-
P/E ratio
-$0.50
EPS
0.66
Beta
-
Dividend rate
Price and volume
Market cap
$349M
Beta
0.66
Financial strength
Current ratio
15.12
Quick ratio
14.979
Management effectiveness
Return on assets (TTM)
-19.63%
Return on equity (TTM)
-28.98%
Valuation
Price to book
2.54
Price to tangible book (TTM)
2.54
Price to free cash flow (TTM)
-10.384
Growth
Earnings per share change (TTM)
-26.73%
3-year earnings per share growth
3.23%
What the Analysts think about Anavex
Analyst Ratings
Majority rating from 2 analysts.
Anavex Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
22.09%
Profit margin
0.00%
NaN%
Anavex Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.14
-$0.12
-$0.11
-$0.13
-
Expected
-$0.17
-$0.15
-$0.15
-$0.11
-$0.14
Surprise
-16.00%
-18.18%
-24.14%
18.18%
-
Anavex News
AllArticlesVideos
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewsWire·2 weeks ago
Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewsWire·1 month ago
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $349M as of July 06, 2024.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of July 06, 2024.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Anavex stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.